Posted 12 October, 2022
Tarsus Pharmaceuticals, Inc. appointed new CEO
CEO Change detected for ticker Nasdaq:TARS in a 8-K filed on 12 October, 2022.
In addition, on October 11, 2022, the Company announced that Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year and, upon such expected transition, Bobak Azamian, the Company's Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board and Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director.
$1.37B
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2022, (the "Effective Date") the Board of Directors (the "Board") of Tarsus Pharmaceuticals, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee (the "Nominating Committee"), expanded the size of the Board from eight to nine directors and appointed Scott Morrison to the Board, effective immediately. Mr. Morrison will serve as a Class III director with a term expiring at the Company's 2023 annual meeting of stockholders or until his successor is duly elected and qualified. Further, effective immediately, the Board appointed Mr. Morrison to serve as Chairperson of the Audit Committee of the Board and as member of the newly formed Commercial Committee of the Board (the "Commercial Committee") (as described below). The Board has determined that Mr. Morrison is independent under the listing standards of the Nasdaq Stock Market and the rules and regulations of the Securities and Exchange Commission (the "SEC") applicable to audit committee members and is an audit committee financial expert as defined under the rules of the SEC. As a non-employee director, Mr. Morrison will receive cash and equity compensation paid by the Company pursuant to its non-employee director compensation policy, as amended, which includes an initial grant of (i) an option to purchase 14,000 shares of the Company's common stock and (ii) 4,000 restricted stock units for the Company's common stock. There are no arrangements or understandings between Mr. Morrison and any other person pursuant to which Mr. Morrison was elected as a director, and there are no transactions between Mr. Morrison and the Company that would require disclosure under Item 404(a) of Regulation S-K. In addition, the Company has entered into an indemnification agreement with Mr. Morrison in connection with his appointment to the Board, which is in substantially the same form as that entered into with the other directors of the Company. Additionally, on the Effective Date, the Board authorized and established the Commercial Committee to oversee the product commercialization efforts of the Company and modified the composition of its committees as follows: -Audit Committee: Rosemary Crane, Wendy Yarno, and Scott Morrison (Chairperson) -Compensation Committee: Bhaskar Chaudhuri, William Link, Wendy Yarno (Chairperson) -Nominating Committee: Bhaskar Chaudhuri, Andrew Goldberg, and William Link (Chairperson) -Science and Technology Committee: Bhaskar Chaudhuri, Andrew Goldberg, William Link, and Elizabeth Yeu-Lin (Chairperson) -Commercial Committee: Scott Morrison, Wendy Yarno, Elizabeth Yeu-Lin, Rosemary Crane (Chairperson) Further, the Board, upon the recommendation of the Nominating Committee, approved the following division and assignment of the Board classes, effective as of the Effective Date: -Class III directors (up for election in 2023): Andrew Goldberg, Scott Morrison, and Wendy Yarno; -Class I directors (up for election in 2024): William Link and Bhaskar Chaudhuri; and -Class II directors (up for election in 2025): Michael Ackermann, Bobak Azamian, Rosemary Crane, and Elizabeth Yeu-Lin. In addition, on October 11, 2022, the Company announced that Michael Ackermann, the Chairperson of the Board, expected to transition off the Board by the end of the 2022 calendar year and, upon such expected transition, Bobak Azamian, the Company's Chief Executive Officer and current member of the Board will be appointed as Chairperson of the Board and Wendy Yarno, current member of the Board, will be appointed as Lead Independent Director.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.